Abstract 15622: Evaluation of Treatment With Fimasartan and Ivabradine in Animal Myocardial Infarction Model using Cardiac Positron Emission Tomography
Background/Objectives: The aim of this study was to evaluate efficacy of fimasartan and ivabradine on reverse remodeling and reducing infarct size in animal myocardial infarction (MI) model, using echocardiography and 18F-labeled mitochondrial voltage sensor positron emission tomography (PET).
Methods: We induced MI in 42 rats, by ligating the left anterior descending artery, and checked their baseline echocardiography and baseline PET cardiac image using 18F-labeled mitochondrial voltage sensor (18F-fluoropentyltriphenylphosphonium salt: 18F-FPTP), 7 days after induction. Rats are grouped into 3 groups according to their prescribed drugs: no drug (n=11), fimasartan 3 mg/kg (n=10), fimasartan 10 mg/kg (n=12). Each designated drugs were administered for 4 weeks, and follow up echocardiography and PET were checked after treatment period. Additional ivabradine group (ivabradine 10 mg/kg, n=9) was defined, and their baseline and follow up echocardiography were checked, in the same manner.
Results: In echocardiographic analysis, treatment with fimasartan 10 mg/kg or ivabradine 10 mg/kg resulted in significant improvement in left ventricular ejection fraction (LVEF), compared with control group (panel A, p<0.001 for both groups), while treatment with fimasartan 3 mg/kg did not. In PET analysis, insignificant decrease in infarct size was observed (panel B), which was proven to be significant in Masson’s trichrome stain (panel C, proportion of infarction in entire left ventricular area: no drug 37.61 ± 5.33 %, fimasartan 3 mg/kg 29.92 ± 6.69 %, fimasartan 10 mg/kg 26.93 ± 5.72 %, p for difference <0.001).
Conclusions: Treatment with fimasartan or ivabradine seems to decrease infarct size and improve LVEF in animal myocardial infarction model, and PET cardiac image using 18F-labeled mitochondrial voltage sensor could be useful in estimating infarct size in myocardial infarction.
Author Disclosures: H. Park: None. Y. Hong: None. J. Kim: None. M. Kim: None. J. Cho: None. H. Yoon: None. K. Kim: None. Y. Ahn: None. M. Jeong: None. J. Cho: None. J. Park: None.
- © 2016 by American Heart Association, Inc.